Seed Funding

Alicia Secor, Female CEO of Atalanta Therapeutics
Investment
From research to development: Atalanta bags $97m to advance two RNAi therapiesFrom research to development: Atalanta bags $97m to advance two RNAi therapies

Atalanta Therapeutics has closed an oversubscribed $97 million Series B financing round to move two RNAi therapies for neurological diseases into clinical trials.

byMillie Nelson, Editor
Feb 10, 2025
|
1 Min Read
funding round on wooden blocks with dollars behind
Investment
The CAR-T promise: Umoja bags $100m in Series C financingThe CAR-T promise: Umoja bags $100m in Series C financing
byMillie Nelson
Jan 28, 2025
1 Min Read
Two cartoons pushing puzzle pieces together
Investment
Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75mChroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m
byMillie Nelson
Dec 23, 2024
1 Min Read
Obesity on a board
Investment
Antag bags $84M in series A funding to drive obesity candidate to the clinicAntag bags $84M in series A funding to drive obesity candidate to the clinic
byMillie Nelson
Dec 19, 2024
1 Min Read
Asia currency
Investment
Eyes on Asia: Sanofi expands China footprint; Takeda buys anemia assetEyes on Asia: Sanofi expands China footprint; Takeda buys anemia asset
byRichard Daverman
Dec 17, 2024
1 Min Read
plan prepare perform
Investment
‘Luck only comes to the most prepared people,’ says AltruBio CEO‘Luck only comes to the most prepared people,’ says AltruBio CEO
byMillie Nelson
Dec 13, 2024
1 Min Read
A whiteboard saying transition
Investment
From Series A to B: Navigating the transition from promise to proof
From Series A to B: Navigating the transition from promise to proof
Nov 20, 2024
|
1 Min Read
byMillie Nelson, Editor
Seed Funding
Europe’s aversity to risk is why the US is ahead, say experts
Europe’s aversity to risk is why the US is ahead
Nov 5, 2024
|
1 Min Read
byMillie Nelson, Editor
VC/PE
'Is the worst behind us?' Financial expert talks biotech funding
'Is the worst behind us?' Financial expert talks biotech funding
Oct 21, 2024
|
1 Min Read
byBrian Scanlan, Dan Stanton
Dollar notes
Investment
The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B
The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B
Oct 17, 2024
|
1 Min Read
byMillie Nelson, Editor
Overhead view of business people working and funding
Investment
$325 million Series C funding in its Arsenal (Biosciences)
$325 million Series C funding in its Arsenal (Biosciences)
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
People making business deals
Partnering
Prometheus and Merck: Under the bonnet of the largest pre-Phase III M&A deal
Under the bonnet of the largest pre-Phase III M&A deal
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Innovation
GSK, Novartis, Calliditas among winners at LSX Awards
GSK, Novartis, Calliditas among winners at LSX Awards
Nov 16, 2023
|
1 Min Read
byMillie Nelson, Editor

BIO-EUROPE COVERAGE

Novo Nordisk sign
Business Strategy
Lessons and blessings: The Novo Nordisk way
Lessons and blessings: The Novo Nordisk way
Michael May, PhD, President, CCRM discusses Canada as a place for life sciences in this video.
Hubs
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
Hervé Ansanay, Biotech Alliance Manager, discusses the features of the RESEAU SATT - SATT NETWORK
Sponsored Content
RESEAU SATT, the Best of French Deep Tech
RESEAU SATT, the Best of French Deep Tech

Latest

Male being kept up at night and unable to sleep
Investment
Interest rates, IPOs, China, or Trump: What’s keeping investors up at night?
Interest rates, IPOs, China, or Trump: What’s keeping investors up at night?
Asia map on the globe
Hubs
Eyes on Asia: Bain Capital buys MTPC, Merck & Co. halts HPV vax, and Illumina
Eyes on Asia: Bain Capital buys MTPC, Merck & Co. halts HPV vax, and Illumina
Francesco De Rubertis, co-founder and partner at Medicxi (left) and Graziano Seghezzi, managing partner at Sofinnova Partners (right).
Investment
Sofinnova and Medicxi talk M&A, patent cliffs, and China
Sofinnova and Medicxi talk M&A, patent cliffs, and China
Mar 17 - Mar 19, 2025
Europe's Largest Springtime Biotech Partnering Event
REGISTER
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated